Moritz Reuter

Moritz Reuter is an Investment Associate at Norgine Ventures, the venture-financing arm of the European specialty-pharmaceutical group Norgine. He came to finance from a scientific background: he earned an MSc in Theoretical Physics (2002–2003) and a PhD in Theoretical Physics (2003–2008), both at Imperial College London, where his published research covered quantum many-body systems treated as quantum channels and the relationship between transfer quality and the spectral gap between ground and excited states.

After his academic work, Reuter moved into financial services, holding roles at Morgan Stanley Wealth Management and Livingston Capital before joining Norgine Ventures as an Investment Associate. In that role he supports the firm's origination, evaluation, and monitoring of debt and debt-like financings for healthcare and life-sciences companies in Europe and the US.

Norgine Ventures itself was launched in 2012 to diversify Norgine's activities and foster innovation in the healthcare sector. It runs a lean team (roughly seven professionals; Peter Stein has served as CEO of Norgine Ventures) and specializes in flexible debt structures for companies that want growth capital without heavy equity dilution.

• Invests via debt and debt-like instruments (venture debt / structured financing) rather than traditional equity, giving founders growth capital with less dilution
• Backs innovative, fast-growing healthcare and life-sciences companies — specialty pharma, diagnostics, and medical devices — "at various stages of their life cycle, both in Europe and in the US"
• Comfortable across Series A–C and dedicated debt rounds; reported activity skews toward later, commercial-stage or scaling companies rather than pure seed
• Deal sizes have ranged from a few million to tens of millions (e.g., the €15M Agendia facility), typically to fund commercial expansion, product roll-out, or working capital
• Firm rationale (Peter Stein, on the Agendia deal): the investment "further reinforces Norgine Ventures' commitment to funding innovative solutions in the healthcare sector"